贝利尤单抗治疗日本和韩国系统性红斑狼疮患者长达7年的开放标签延续研究
该III期开放标签延续研究评估贝利尤单抗在日本和韩国SLE患者中的长期安全性和疗效,142例患者接受静脉贝利尤单抗10 mg/kg每28天一次,最长7年。结果显示 favourable 安全性特征和治療反應得以维持,SRI4应答率从第1年第24周的47.8%升至第6年第48周的68.2%。
要点
- 贝利尤单抗治疗日本和韩国SLE患者长达7年,安全性特征良好。
- SRI4应答率随治疗时间增加,第6年第48周达68.2%。
- 严重SLE flare发生率为14.8%,大多数患者发生不良事件。
核心结论
- 贝利尤单抗在日本和韩国SLE患者中长达7年的治疗维持了良好的安全性特征和治疗应答。
研究设计与样本
- III期开放标签延续研究(BEL114333;NCT01597622),纳入BEL113750或BEL112341的合格完成者,静脉给予贝利尤单抗10 mg/kg每28天一次,最长7年,主要终点为安全性。
主要发现
- 142例入组患者中73.2%完成研究,97.9%发生不良事件,33.8%发生严重不良事件。
- SRI4应答率第1年第24周为47.8%,第6年第48周为68.2%,SELENA-SLEDAI应答者比例提示疾病活动度降低。
- Physician Global Assessment无恶化/无新器官损伤的患者比例在整个研究期间保持稳定,严重SLE flare发生率为14.8%。
- 基线泼尼松等效剂量>7.5 mg/day的患者(n=81)中,基线后任意时间每日剂量≤7.5 mg/day或较基线降低50%的中位天数为584天(最小0,最大2267)。
关键数值与推荐
- SRI4应答率:第1年第24周47.8%,第6年第48周68.2%。
- 严重SLE flare发生率:14.8%。
- 基线泼尼松等效剂量>7.5 mg/day患者(n=81)中,每日剂量≤7.5 mg/day或较基线降低50%的中位天数为584天(0,2267)。
临床怎么用
- 长期使用贝利尤单抗治疗日本和韩国SLE患者可维持疾病活动度降低和器官损伤稳定。
- 贝利尤单抗治疗期间需关注不良事件,多数患者发生不良事件,约三分之一发生严重不良事件。
- 基线泼尼松剂量>7.5 mg/day的患者中,贝利尤单抗治疗有助于实现激素减量至≤7.5 mg/day或较基线降低50%。
局限性
- 本研究为开放标签延续研究,基于观察数据分析,未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) from Japan and South Korea. METHODS: In this phase III, open-label continuation study (BEL114333; NCT01597622), eligible completers of BEL113750 (NCT01345253) or BEL112341 (NCT01484496) received intravenous belimumab 10 mg/kg every 28 days for ≤7 years. Primary endpoint was safety. Secondary endpoints: SLE Responder Index (SRI)4 response rate, proportion of patients meeting individual SRI4 criteria, SLE flares and prednisone use. Analyses were based on observed data from the first belimumab exposure (either in parent or current study) through to study end. RESULTS: Of 142 enrolled patients who received belimumab, 73.2% completed the study. The study population comprised patients with moderate SLE, mean (SD) Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) baseline score of 9.3 (3.9) and 98.6% receiving corticosteroids. Most patients (97.9%) experienced adverse events (AEs); 33.8% experienced serious AEs. Increase in SRI4 (Year 1, Week 24: 47.8%; Year 6, Week 48: 68.2%) and SELENA-SLEDAI responders suggested reductions in disease activity. Proportions of patients with no worsening in Physician Global Assessment/no new organ damage remained stable throughout. Severe SLE flares occurred in 14.8% of patients. Among patients with baseline prednisone-equivalent dose >7.5 mg/day (n=81), the median (min, max) number of days anytime post-baseline that the daily dose was ≤7.5 mg/day or had been reduced by 50% from baseline was 584 (0, 2267). CONCLUSIONS: Favourable safety profile and treatment responses were maintained for ≤7 years in patients with SLE from Japan and South Korea.
引用
- Tanaka Y, Bae SC, Bass D, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 2021. PMID: 34215703. doi:10.1136/rmdopen-2021-001629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。